Zydus & Torrent Partner to Co-Market Semaglutide Injection

Zydus Lifesciences Limited and Torrent Pharmaceuticals Limited today announced a licensing and supply agreement to co?market semaglutide injection in India.

Under the pact, Zydus will manufacture and supply the drug while Torrent Pharma will use its strong chronic therapy presence to market the product under the brand Sembolic.

Zydus will continue to market the semaglutide injection in India under its brands Semaglyn, Mashema, and Alterme. Torrent Pharma’s semi?exclusive rights allow it to promote and sell the product nationwide under its own brand. As part of the deal, Torrent Pharma will pay an upfront licensing fee to Zydus.

Also Read: Ozempic Patent Expiry Drives Surge in Pharma Stocks Ahead of Launch

Zydus has developed an innovative semaglutide injection (15 mg/3 ml) in a prefilled cartridge that works with a reusable, patient?friendly pen device. This unique delivery system enables all dose strengths for both diabetes and weight management through one single device, improving convenience, adherence, and long?term compliance—key goals in chronic disease care.

Semaglutide is indicated for adults with type 2 diabetes mellitus who need better blood sugar control alongside diet and exercise, including those for whom metformin is unsuitable. The drug is also approved for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with related conditions like hypertension or dyslipidemia. The Indian semaglutide injection market is rapidly evolving as more patients seek advanced GLP?1 therapies.

This collaboration brings together Zydus’s development and manufacturing strength with Torrent Pharma’s field reach, with a shared aim to improve patient access to modern therapies for metabolic disorders.